Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 36480032)

  • 1. Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
    Schatz J; Ladinig A; Fietkau R; Putz F; Gaipl US; Frey B; Derer A
    Strahlenther Onkol; 2023 Dec; 199(12):1140-1151. PubMed ID: 36480032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
    Heynckes S; Daka K; Franco P; Gaebelein A; Frenking JH; Doria-Medina R; Mader I; Delev D; Schnell O; Heiland DH
    BMC Cancer; 2019 Feb; 19(1):117. PubMed ID: 30709339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.
    Rubner Y; Muth C; Strnad A; Derer A; Sieber R; Buslei R; Frey B; Fietkau R; Gaipl US
    Radiat Oncol; 2014 Mar; 9(1):89. PubMed ID: 24678590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma.
    Wang X; Guo G; Guan H; Yu Y; Lu J; Yu J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):87. PubMed ID: 30777100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells.
    Miyazaki T; Ishikawa E; Matsuda M; Sugii N; Kohzuki H; Akutsu H; Sakamoto N; Takano S; Matsumura A
    Brain Tumor Pathol; 2020 Apr; 37(2):41-49. PubMed ID: 31980975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detailed
    Stoll E; Hader M; Rückert M; Weissmann T; Lettmaier S; Putz F; Hecht M; Fietkau R; Rosin A; Frey B; Gaipl US
    Int J Hyperthermia; 2022; 39(1):796-805. PubMed ID: 35676615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
    Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
    Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential.
    Yang T; Kong Z; Ma W
    Hum Vaccin Immunother; 2021 Feb; 17(2):546-553. PubMed ID: 32643507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated Radiotherapy Upregulates Several Immune Checkpoint Molecules in Head and Neck Squamous Cell Carcinoma Cells Independently of the HPV Status While ICOS-L Is Upregulated Only on HPV-Positive Cells.
    Wimmer S; Deloch L; Hader M; Derer A; Grottker F; Weissmann T; Hecht M; Gostian AO; Fietkau R; Frey B; Gaipl US
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
    Vaidya KS; Mitten MJ; Zelaya-Lazo AL; Oleksijew A; Alvey C; Falls HD; Mishra S; Palma J; Ansell P; Phillips AC; Reilly EB; Anderson M; Boghaert ER
    J Neurooncol; 2021 Apr; 152(2):233-243. PubMed ID: 33517558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
    Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
    Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
    Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A
    Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
    Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
    Front Immunol; 2021; 12():637146. PubMed ID: 34025646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia.
    Dang W; Xiao J; Ma Q; Miao J; Cao M; Chen L; Shi Y; Yao X; Yu S; Liu X; Cui Y; Zhang X; Bian X
    Brain Tumor Pathol; 2021 Jul; 38(3):189-200. PubMed ID: 34231121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.
    Yahyanejad S; King H; Iglesias VS; Granton PV; Barbeau LM; van Hoof SJ; Groot AJ; Habets R; Prickaerts J; Chalmers AJ; Eekers DB; Theys J; Short SC; Verhaegen F; Vooijs M
    Oncotarget; 2016 Jul; 7(27):41251-41264. PubMed ID: 27183910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
    Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y
    EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma.
    Iorgulescu JB; Gokhale PC; Speranza MC; Eschle BK; Poitras MJ; Wilkens MK; Soroko KM; Chhoeu C; Knott A; Gao Y; Lim-Fat MJ; Baker GJ; Bonal DM; Nguyen QD; Grant GRL; Ligon KL; Sorger PK; Chiocca EA; Anderson AC; Kirschmeier PT; Sharpe AH; Freeman GJ; Reardon DA
    Clin Cancer Res; 2021 Jan; 27(1):276-287. PubMed ID: 33239433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.